ARGLU1

ARGLU1 is a bifunctional nuclear protein that couples transcriptional regulation with alternative splicing control, with essential roles in embryonic development and neural differentiation. Its glutamate-rich C-terminus coactivates nuclear receptors (estrogen receptor, glucocorticoid receptor) through direct interaction with the Mediator subunit MED1, while its arginine-rich N-terminus binds RNA and splicing factors to regulate alternative splicing of neurogenesis and DNA damage pathway genes, including Mdm2/Mdm4, whose mis-splicing upon ARGLU1 loss derepresses p53 and causes apoptosis-driven microcephaly (PMID:21454576, PMID:30698747, PMID:37612280). ARGLU1 autoregulates its own expression via an ultraconserved element within a retained intron and an intronic sisRNA that sequesters ARGLU1 protein to nuclear speckles, relieving its splicing-inhibitory activity at its own locus (PMID:27899669, PMID:36533631). ARGLU1 also promotes promoter-proximal RNA Pol II pausing by inhibiting the JMJD6–BRD4 interaction, thereby facilitating DNA damage repair and transcriptional repression, and is itself subject to K11-linked ubiquitin-mediated degradation by the DTL/CRL4A E3 ligase complex, which activates Notch signaling (PMID:38520408, PMID:38218284).

1. 2011 High

   Establishing ARGLU1 as a transcriptional coactivator: the first evidence that ARGLU1 directly binds MED1 and is recruited in a ligand-dependent manner to estrogen receptor target gene promoters resolved its identity as a Mediator-associated nuclear receptor coactivator.

   Evidence Co-immunoprecipitation, direct binding assay, ChIP-reChIP, reporter assays in breast cancer cells

   PMID:21454576

   Open questions at the time

   • Structural basis of the ARGLU1–MED1 interaction unresolved
   • Whether ARGLU1 coactivation extends beyond ER to other nuclear receptors was untested
   • Mechanism by which ARGLU1 enhances transcriptional output unknown
2. 2017 High

   Discovery of ARGLU1 autoregulatory splicing revealed that ARGLU1 protein feeds back on its own pre-mRNA via a UCE-containing retained intron to shift splicing toward NMD-susceptible isoforms, establishing a homeostatic circuit.

   Evidence CRISPR/Cas9 UCE mutagenesis, minigene reporters, overexpression and functional knockout with RNA isoform analysis

   PMID:27899669

   Open questions at the time

   • Whether ARGLU1 directly binds the UCE RNA element or acts through splicing factor intermediaries was unclear
   • Physiological contexts in which autoregulation is rate-limiting were not defined
3. 2019 High

   Domain dissection and in vivo genetics established ARGLU1 as a bifunctional protein — its arginine-rich N-terminus mediates RNA/splicing-factor binding while its glutamate-rich C-terminus coactivates GR and other nuclear receptors — and demonstrated that ARGLU1 loss is embryonic lethal in mice and causes neurodevelopmental defects across species.

   Evidence Biochemical domain mapping, reporter assays, RNA-seq in ARGLU1-depleted neural cells, mouse knockout, zebrafish morpholino knockdown

   PMID:30698747

   Open questions at the time

   • Identity of direct RNA targets of the N-terminal domain not catalogued
   • Whether splicing and coactivation functions are separable in vivo was not tested
   • Mechanism linking ARGLU1 to specific neurodevelopmental gene networks undefined
4. 2019 Medium

   Glucocorticoid-induced alternative splicing in neural cells was shown to be largely ARGLU1-dependent, distinguishing ARGLU1's splicing-regulatory role from GR's direct transcriptional targets.

   Evidence RNA-seq epistasis comparing dexamethasone-treated wild-type vs ARGLU1-depleted neural cells

   PMID:30698747

   Open questions at the time

   • Whether GR physically recruits ARGLU1 to splicing sites or acts indirectly was unknown
   • Single-lab finding awaiting independent replication
5. 2021 Medium

   ARGLU1 was linked to DNA mismatch repair transcription by showing it potentiates SP1 and YY1 recruitment to promoters of MLH3, MSH2, MSH3, and MSH6, extending its transcriptional role beyond nuclear receptor targets.

   Evidence ChIP for SP1/YY1, overexpression, gene expression analysis

   PMID:34157484

   Open questions at the time

   • Whether ARGLU1 directly contacts SP1/YY1 or acts through Mediator was not determined
   • Functional consequence for mismatch repair activity not shown
6. 2022 Medium

   An intronic sisRNA was found to bind ARGLU1 protein and relocalize it to nuclear speckles, relieving its splicing-inhibitory activity at its own locus — adding a spatial sequestration layer to the autoregulatory circuit discovered in 2017.

   Evidence RNA-protein binding assay, nuclear speckle fluorescence localization, functional splicing assay in human cells

   PMID:36533631

   Open questions at the time

   • Whether sisRNA-mediated sequestration affects ARGLU1 activity at non-self target genes was not tested
   • Stoichiometry and dynamics of sisRNA–ARGLU1 interaction in vivo unknown
7. 2023 High

   Conditional knockout in mouse cortex resolved the embryonic lethal phenotype: ARGLU1 loss causes aberrant splicing of Mdm2 and Mdm4 (loss of p53-binding exons, triggering NMD), derepressing p53 and driving apoptosis-dependent microcephaly — rescued by p53 co-deletion.

   Evidence Conditional cortical knockout mouse, RNA-seq, p53 double-mutant genetic rescue, immunohistochemistry

   PMID:37612280

   Open questions at the time

   • Whether the Mdm2/Mdm4 splicing defect is a direct or indirect consequence of ARGLU1 loss was not distinguished
   • Contribution of ARGLU1 splicing targets beyond Mdm2/Mdm4 to the microcephaly phenotype unclear
8. 2024 Medium

   ARGLU1 was shown to enhance promoter-proximal RNA Pol II pausing by inhibiting the JMJD6–BRD4 interaction, establishing a transcriptional pausing mechanism and connecting ARGLU1 to DNA damage repair and genotoxic drug resistance.

   Evidence Pol II ChIP for pausing index, co-immunoprecipitation of JMJD6–BRD4, DNA damage repair assays, overexpression/knockdown in cancer cells

   PMID:38520408

   Open questions at the time

   • Whether pausing regulation is genome-wide or locus-specific not resolved
   • Direct biochemical mechanism of JMJD6–BRD4 disruption by ARGLU1 not defined
   • Single-lab finding
9. 2024 High

   DTL/CRL4A was identified as the E3 ligase that ubiquitinates ARGLU1 via K11-linked chains, targeting it for degradation and thereby activating CSL-dependent Notch signaling — revealing post-translational control of ARGLU1 abundance.

   Evidence Mass spectrometry interaction screen, co-immunoprecipitation, K11 ubiquitin linkage mapping, siRNA epistasis, in vivo tumor assays in HNSCC

   PMID:38218284

   Open questions at the time

   • How ARGLU1 represses Notch/CSL signaling mechanistically is unknown
   • Whether K11 ubiquitination is cell-cycle regulated or stimulus-dependent not tested
10. 2025 Medium

    Adenovirus E1A was shown to directly bind ARGLU1 (recombinant protein interaction), co-opting its Pol II pausing function at viral promoters for transcriptional repression and impairing ARGLU1-mediated DNA damage repair — the first viral hijacking of ARGLU1.

    Evidence GST-pulldown with recombinant proteins, viral promoter reporter, E1A mutant (dl1102) epistasis, DNA damage repair assay

    PMID:41186411

    Open questions at the time

    • Whether E1A targets ARGLU1 splicing functions in addition to pausing is unknown
    • Relevance to adenovirus replication kinetics in vivo not established

• Key unresolved questions include the structural basis of ARGLU1's bifunctional architecture, the genome-wide direct RNA targets of its arginine-rich domain, whether its splicing and transcriptional functions are separable in vivo, and how its K11-linked ubiquitination is regulated in different physiological contexts.
• No structural model of ARGLU1 or its complexes exists
• Direct RNA target repertoire not mapped by CLIP or equivalent
• In vivo separation-of-function alleles for N- vs C-terminal activities not generated